Nuformix PLC - Dr Chris Blackwell Appointed NED

11th May 2018, 06:00

RNS Number : 7341N
Nuformix PLC
11 May 2018
 

Nuformix plc

("Nuformix" or "the Company")

 

Board Announcement

 

Nuformix appoints Dr Chris Blackwell as Non-executive Director

 

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs today announced that it has appointed Dr Christopher Blackwell as a Non-executive Director. The appointment reflects Nuformix's ambition and trajectory as it embarks on a period of growth, building on its position of developing innovative cocrystal-based therapies. Chris joins the Board with immediate effect.

 

Dr Chris Blackwell, B.Sc, Ph.D. served as CEO of Vectura Group Plc from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion. Chris presided over a period of significant growth including deal-making (including a $375m out-licensing agreement with Novartis, Europe's largest biotech deal of 2005), fund-raising, M&A and corporate development that transformed Vectura's capabilities from research led technology development to commercially driven pharmaceutical development. Chris' track record and experience will guide Nuformix through its next stage of growth. 

Chris has also held previous executive roles at Glaxo Group Research Ltd and Hoffman La-Roche. He also served as Senior Independent Non-executive Director at AGI Therapeutics Ltd between July 2006 and February 2012 and is Executive Chairman of Circadian Therapeutics Ltd.

 

No further information is required to be disclosed pursuant to LR 9.6.13 R.

 

Dr Chris Blackwell, commenting, said: "It's a pleasure to be joining the Board at this exciting time and to support the management team with the development of its drug pipeline, particularly given Nuformix's approach to diseases such as fibrosis, with its NXP002 programme, targeting large unmet needs in therapeutic markets with significant commercial potential."

 

Commenting, Dr Dan Gooding, Chief Executive Officer, Nuformix, said: "I'm delighted to announce Chris's appointment. He will provide the Board with invaluable experience in the public markets and in achieving successful growth as an innovative pharmaceutical development company. Chris's extensive knowledge and experience are simply a perfect fit with our corporate development goals and his arrival demonstrates the impact Nuformix hopes to achieve in the commercialisation of our product pipeline."

 

The Company has entered into an agreement with Chris Blackwell whereby he will be issued with warrants to subscribe for 3,000,000 new ordinary shares of 0.1 pence in the capital of the Company conditional upon him continuing to act as Non-executive Director of the Company on 11 May 2019 ("Warrants"). The Warrants are exercisable from 11 May 2019 to 11 May 2021, at an exercise price of 4 pence per ordinary share.

 

Follow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX

and www.nuformix.com

 

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

 

 

Enquiries:

 

Nuformix plc

Dr Dan Gooding, Chief Executive Officer

+44 (0)1223 423667

 

Gable Communications Ltd

John Bick / Justine James

+44 (0)20 7193 7463

 

 

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs.   Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

 

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

 

Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.  Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFFTEFIILIT ]]>

Companies mentioned in this announcement

Comments

info
Login or register to post comments